Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
University Library
Adelaide Festival of Ideas
Barr Smith Press
Friends of the University of Adelaide Library
Library Publications
Internal documents (Library staff only)
Library images
Library reports and papers
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 11-20 of 20 (Search time: 0.003 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Muller, M.
;
Cortes, J.
;
Kim, D.
;
Druker, B.
;
Erben, P.
;
Pasquini, R.
;
Branford, S.
;
Hughes, T.
;
Radich, J.
;
Ploughman, L.
;
Mukhopadhyay, J.
;
Hochhaus, A.
2008
Long-term imatinib therapy promotes bone formation in CML patients
Fitter, S.
;
Dewar, A.
;
Kostakis, P.
;
To, L.
;
Hughes, T.
;
Roberts, M.
;
Lynch, K.
;
Vernon-Roberts, B.
;
Zannettino, A.
2009
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Apperley, J.
;
Cortes, J.
;
Kim, D.
;
Roy, L.
;
Roboz, G.
;
Rosti, G.
;
Bullorsky, E.
;
Abruzzese, E.
;
Hochhaus, A.
;
Heim, D.
;
De Souza, C.
;
Larson, R.
;
Lipton, J.
;
Khoury, J.
;
Kim, H.
;
Sillaber, C.
;
Hughes, T.
;
Erben, P.
;
Tornout, J.
;
Stone, R.
2007
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Venables, A.
;
Zrim, S.
;
Zannettino, A.
;
Lynch, K.
;
Manley, P.
;
Hughes, T.
2013
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects
Vandyke, K.
;
Fitter, S.
;
Drew, J.
;
Fukumoto, S.
;
Schultz, C.
;
Sims, N.
;
Yeung, D.
;
Hughes, T.
;
Zannettino, A.
2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Parkinson, I.
;
Grigg, A.
;
Szer, J.
;
Taylor, K.
;
Hermann, R.
;
Seymour, J.
;
Arthur, C.
;
Joske, D.
;
Lynch, K.
;
Hughes, T.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia
Esposito, N.
;
Colavita, I.
;
Quintarelli, C.
;
Sica, A.
;
Peluso, A.
;
Luciano, L.
;
Picardi, M.
;
Vecchio, L.
;
Buonomo, T.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Russo, D.
;
Branford, S.
;
Saglio, G.
;
Vaz de Melo, J.
;
Martinelli, R.
;
Ruoppolo, M.
;
Kalebic, T.
;
Martinelli, G.
;
et al.
2017
Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia
Banjar, H.
;
Ranasinghe, D.
;
Brown, F.
;
Adelson, D.
;
Kroger, T.
;
Leclercq, T.
;
White, D.
;
Hughes, T.
;
Chaudhri, N.
;
Speletas, M.
2017
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
Hughes, A.
;
Clarson, J.
;
Tang, C.
;
Vidovic, L.
;
White, D.
;
Hughes, T.
;
Yong, A.
Discover
Author
10
Branford, S.
7
Hochhaus, A.
7
Radich, J.
7
White, D.
6
Kim, D.
5
Larson, R.
5
Saglio, G.
4
Baccarani, M.
4
Grigg, A.
4
Lynch, K.
.
next >
Subject
20
Female
19
Imatinib Mesylate
19
Middle Aged
18
Aged
17
Benzamides
17
Piperazines
16
Leukemia, Myelogenous, Chronic, B...
15
Antineoplastic Agents
8
Adolescent
8
Protein Kinase Inhibitors
.
next >
Date issued
10
2010 - 2017
10
2002 - 2009